Experimental COVID-19 Vaccine Protects Upper and Lower Airways in Nonhuman Primates | NIH: National Institute of Allergy and Infectious Diseases

Experimental COVID-19 Vaccine Protects Upper and Lower Airways in Nonhuman Primates | NIH: National Institute of Allergy and Infectious Diseases

Tuesday, July 28, 2020 Experimental COVID-19 Vaccine Protects Upper and Lower Airways in Nonhuman Primates Two doses of an experimental vaccine to prevent coronavirus disease 2019 (COVID-19) induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2, report NIAID scientists. SARS-CoV-2 is the virus that causes COVID-19.  The candidate vaccine, mRNA-1273, was co-developed by scientists at the NIAID Vaccine Research Center and at Moderna, Inc., Cambridge, Massachusetts. The animal study results published online today in the New England Journal of Medicine complement recently reported interim results from an NIAID-sponsored Phase 1 clinical trial of mRNA-1273.